Omeros Corporation is a biopharmaceutical company based in Seattle, Washington, that discovers and develops small-molecule and protein therapeutics. Its marketed product is an additive used in irrigation solutions during eye surgery, and its research pipeline has focused on inflammation, complement-mediated disorders and conditions affecting the central nervous system. The company serves physicians, hospitals and surgical centres that use its ophthalmic product, while its development programmes address unmet medical needs across several therapeutic areas.
The shares are listed on the London Stock Exchange in UK under the code 0KBU, and the price on this page is in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Market X-Ray · price-based
Fair price profile
Ranks #1709 of 3788 on the London Stock Exchange · confidence Medium
What this score is, and is not
It describes how this stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is. That fundamental X-Ray needs financial statements, which we do not have for UK yet.
TrendStrong
81/100
Trading above its long-term averages and near its highs.
See the numbers →
Above 200-day average29.4%
From 52-week high-17.0%
MomentumStrong
88/100
Rising faster than most stocks on this exchange.
See the numbers →
3-month return50.5%
6-month return18.0%
Stability (higher is calmer)Weak
13/100
Volatile, with deep drawdowns.
See the numbers →
Volatility, 1 year (lower is calmer)95.4%
Worst drawdown, 1 year (smaller is calmer)-50.5%
LiquidityWeak
30/100
Thinly traded: prices can jump and exits can be hard.
See the numbers →
Avg daily value traded0.10M USD
Zero-volume days0.0%
IncomeNone
–/100
Pays no dividend.
See the numbers →
Years with dividends0
Price-based X-Ray. The fundamental X-Ray (financial health, valuation, growth, fair value) is available for US stocks today. It will follow for UK when fundamentals data for this market is added. All UK stocks.
52-wk range 6.86 – 21.48Daily closes, split-adjusted
Signals
50-day average18.52
200-day average13.35
Golden/death cross (60d)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.79
Technical summary
Daily
Neutral
5 bullish · 4 neutral · 6 bearish
Weekly
Strongly bullish
5 bullish · 1 neutral · 1 bearish
Monthly
Strongly bullish
1 bullish · 0 neutral · 0 bearish
Moving averages (daily)
SMA 10
16.95
Bullish
EMA 10
17.11
Bullish
SMA 20
18.00
Bearish
EMA 20
17.65
Bearish
SMA 50
18.52
Bearish
EMA 50
17.37
Bearish
SMA 100
14.75
Bullish
EMA 100
15.89
Bullish
SMA 200
13.35
Bullish
EMA 200
–
n/a
Oscillators (daily)
RSI (14)
45.92
Neutral
MACD (12, 26)
-0.52
Bearish
Momentum (12)
-12.82
Bearish
Stochastic %K (14)
33.25
Neutral
Williams %R (14)
-66.75
Neutral
CCI (20)
-58.57
Neutral
Pivot points (classic, last session)
S3
15.97
S2
16.23
S1
16.76
Pivot
17.02
R1
17.55
R2
17.81
R3
18.34
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
Prices are end-of-day closes in USD. Educational only, not financial advice.
